Ming-Zhu Jiang

Ming-Zhu Jiang

Auto-generated profile, based on publicly available information

Ming-Zhu Jiang

Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Department of neurosurgery, Taihe Hospital, School of Pharmaceutical Sciences, Hubei University of Medicine, Shiyan, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
MJMingzhu Jiang
Mingzhu Jiang
YFYing Feng
Ying Feng
JWJingxian Wang
Jingxian Wang
XXXiang Xu
Xiang Xu
ZLZegan Liu
Zegan Liu
SDShiming Du
Shiming Du
Chronic alcohol consumption can lead to alcohol live disease (ALD). Steatosis is a critical hallmark of ALD, making it an important stage for therapeutic intervention. Saikosaponin A (SSa), a compound found in Radix Bupleuri, has previously shown promising hepatoprotective, anti-inflammatory, and antioxidant properties. However, its role in ALD remains understudied. We employ cell-based screening models and a chronic-plus-binge ethanol-fed mouse model to investigate the protective mechanisms of SSa and its metabolite Saikogenin A (SGA), against ethanol-induced hepatocyte injury. Our RNA-seq analysis in mice unveils that SSa primarily acts through the mTOR and PPAR-α signaling pathways in the liver. Biophysical assays and loss of function experiments confirm SGA directly binds to and modulates the activity of SIRT1 protein, mitigating ethanol-induced cell injury via the SIRT1-mTOR-PPAR-α axis. Furthermore, SGA displays a survival prolonging advantage compared to resveratrol for treating ALD. This suggests SGA holds promise as a potential therapeutic agent for ALD.

7 February 2024 in Research Square
Verified
Preprint
Open access
PDF file
YWYufeng Wang
Yufeng Wang
MJMing-Zhu Jiang
Ming-Zhu Jiang
YFYing Feng
Ying Feng
JWJing-Xian Wang
Jing-Xian Wang
XXXiang Xu
Xiang Xu
SDShi-Ming Du
Shi-Ming Du
Chronic alcohol consumption leads to a spectrum of liver disorders, including steatosis, inflammation, and fibrosis, collectively known as alcohol liver disease (ALD). Steatosis is a critical hallmark of ALD, making it an important target for therapeutic intervention. Saikosaponin A (SSa), a compound found in Radix Bupleuri, has previously shown promising hepatoprotective, anti-inflammatory, and antioxidant properties. However, its role in ALD remains understudied, with direct regulatory targets and mechanisms yet to be fully elucidated in vivo. Moreover, the instability of SSa in gastric juice raises questions about the efficacy of oral SSa solutions. In this study, we employed cell-based screening models and a chronic-plus-binge ethanol-fed mouse model to investigate the protective mechanisms of SSa and its metabolite Saikogenin A (SGA), against ethanol-induced hepatocyte injury. Our RNA-seq analysis in mice unveiled that SSa primarily acts through the mTOR and PPAR-α signaling pathways in the liver. Biophysical assays and loss-of-function experiments confirmed that SGA directly binds to and modulates the activity of the SIRT1 protein, mitigating ethanol-induced cell injury via the SIRT1-mTOR-PPAR-α axis. Furthermore, our liver-specific knockdown of SIRT1 in an ALD mouse model demonstrated that the action of the liver proteins affected by oral SSa solutions is mediated through SIRT1. Significantly, SGA displayed a superior safety profile for hepatocytes compared to SSa. Our findings highlight the role of SGA in binding to the SIRT1 protein and enhancing its activity, thereby regulating hepatic fatty acid oxidation and adipogenesis in ALD. This suggests that SGA holds promise as a potential therapeutic agent for ALD.